BTBP(SH:600161) 智通财经网·2025-08-05 09:19Core Viewpoint - TianTan Bio (600161.SH) announced that its subsidiary Chengdu Rongsheng Pharmaceutical has completed clinical trials for its product "Recombinant Human Coagulation Factor VIII for Injection" in the population under 12 years old, achieving significant results in reducing bleeding frequency and improving joint health and quality of life scores [1] Group 1: Clinical Trial Results - The Phase III clinical trial results for "Recombinant Human Coagulation Factor VIII" in the under-12 population show that routine preventive treatment significantly reduces bleeding frequency in children [1] - Improvements were observed in joint health scores (HJHS), target joint count, and quality of life scores (CHO-KLAT) for patients using the product [1] - The product effectively controls breakthrough bleeding during the prevention period [1] Group 2: Safety Analysis - Safety analysis indicates that the drug demonstrates good safety for patients with Hemophilia A in the clinical application process [1]